Our finding that CX4945 modulates mitochondrial protein biogenesis via the DYRK1A-TOM70 axis activating import of MIA and also of presequence precursor substrates might also have clinical implications, as the inhibitor is used in clinical trials for the treatment of various cancers and COVID-1951–53. This evidence concerns the gene DYRK1A and cancer.